Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.50 |
| ▸ | POLQ | O75417 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | PPIB | P23284 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1760632 | 0.86 | KMT2A (0.58) | KMT2APOLQMEN1ALDH1A1CYP3A4 | |
| SCHEMBL8472209 | 0.86 | SMN1; SMN2 (0.54) | KMT2APOLQMEN1ALDH1A1 | |
| SCHEMBL307215 | 0.82 | KMT2A (0.54) | KMT2APOLQMEN1ALDH1A1CYP3A4 | |
| SCHEMBL23704985 | 0.82 | HPGD (0.45) | KMT2AMEN1ALDH1A1 | |
| SCHEMBL20680527 | 0.82 | NOTUM (0.37) | KMT2APOLQALDH1A1PPIB | |
| SCHEMBL8179642 | 0.82 | PPIB (0.51) | KMT2AALDH1A1PPIB | |
| SCHEMBL1006752 | 0.82 | LMNA (0.48) | KMT2AMEN1ALDH1A1 | |
| SCHEMBL6659655 | 0.81 | KMT2A (0.53) | KMT2APOLQMEN1ALDH1A1CYP3A4 | |
| SCHEMBL8181301 | 0.80 | HSD17B2 (0.55) | — | |
| SCHEMBL12679968 | 0.80 | KCNA5 (0.44) | KMT2APOLQMEN1ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1957498-B1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | METHYLGENE INC (CA) | 2017-02-15 | — | — | EP | disclosed |
| EP-1957498-B1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | METHYLGENE INC (CA) | 2017-02-15 | — | — | EP | disclosed |
| CN-101796055-B | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE INC | 2013-09-04 | — | — | CN | disclosed |
| US-8329726-B2 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE INC. (CA) | 2012-12-11 | — | — | US | disclosed |
| US-8329726-B2 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE INC. (CA) | 2012-12-11 | — | — | US | disclosed |
| US-8329726-B2 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE INC. (CA) | 2012-12-11 | — | — | US | disclosed |
| US-20120083482-A1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | METHYLGENE INC. | 2012-04-05 | — | — | US | disclosed |
| US-20120083482-A1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | METHYLGENE INC. | 2012-04-05 | — | — | US | disclosed |
| US-20120083482-A1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | METHYLGENE INC. | 2012-04-05 | — | — | US | disclosed |
| US-8093264-B2 | Fused heterocycles as inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE INC. (CA) | 2012-01-10 | — | — | US | disclosed |
| US-7560557-B2 | Process for the manufacture of quinoline derivatives | ACTIVE BIOTECH AG (SE) | 2009-07-14 | — | — | US | disclosed |
| EP-1511732-B9 | PROCESS FOR THE MANUFACTURE OF QUINOLINE DERIVATIVES | ACTIVE BIOTECH AB (SE) | 2008-11-12 | — | — | EP | disclosed |
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE, INC. | 2007-01-04 | — | — | US | disclosed |
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE, INC. | 2007-01-04 | — | — | US | disclosed |
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE, INC. | 2007-01-04 | — | — | US | disclosed |
| EP-1511732-B1 | PROCESS FOR THE MANUFACTURE OF QUINOLINE DERIVATIVES | ACTIVE BIOTECH AB (SE) | 2006-12-20 | — | — | EP | disclosed |
| US-20050215586-A1 | Process for the manufacture of quinoline derivatives | ACTIVE BIOTECH AB (SE) | 2005-09-29 | — | — | US | disclosed |
| US-6875869-B2 | Process for the manufacture of quinoline derivatives | ACTIVE BIOTECH AB (SE) | 2005-04-05 | — | — | US | disclosed |
| US-20040034227-A1 | Process for the manufacture of quinoline derivatives | ACTIVE BIOTECH AB (SE) | 2004-02-19 | — | — | US | disclosed |
| US-5912349-A | Process for the preparation of roquinimex | PHARMACIA & UPJOHN COMPANY (US) | 1999-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | HGF, MET, FLT1 | KMT2A 3391/4885POLQ 1701/4885MEN1 3655/4885 |
| US-20120083482-A1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | HGF, MET, KDR | KMT2A 2894/4885POLQ 3249/4885MEN1 4271/4885 |
| US-20040034227-A1 | Process for the manufacture of quinoline derivatives | CYP4F3, HTR3C, CYP3A43 | KMT2A 2359/4885POLQ 403/4885MEN1 2749/4885 |
| US-20050215586-A1 | Process for the manufacture of quinoline derivatives | ADH5, RPS4Y1, CYP4F3 | KMT2A 2223/4885POLQ 199/4885MEN1 2560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.